ORAL THIN FILM DRUG DELIVERY SYSTEMS FOR THROMBOSIS THERAPY: A COMPREHENSIVE REVIEW

Thrombosis refers to the pathological formation of blood clots within the arterial or venous circulation and represents one of the most significant global health challenges. It underlies a wide range of life-threatening cardiovascular and cerebrovascular disorders, including myocardial infarction, ischemic stroke, deep vein thrombosis (DVT), and pulmonary embolism (PE)¹. Epidemiological studies indicate that thrombotic disorders are responsible for approximately one-quarter of all deaths worldwide, highlighting their enormous clinical and socioeconomic burden². The incidence of thrombosis continues to rise due to increasing life expectancy, sedentary lifestyles, obesity, diabetes mellitus, cancer, prolonged immobilization, and widespread use of invasive medical procedures.Pharmacological management remains the cornerstone of thrombosis prevention and treatment. Depending on the type and severity of thrombosis, antiplatelet agents, anticoagulants, and fibrinolytic drugs are prescribed either alone or in combination. Antiplatelet agents are primarily used in arterial thrombosis, while anticoagulants are essential for the prevention and treatment of venous thromboembolism. Fibrinolytic agents are reserved for acute thrombotic emergencies such as massive pulmonary embolism or acute ischemic stroke. Despite their proven efficacy, conventional antithrombotic therapies often suffer from significant limitations related to their dosage forms³.Oral tablets and capsules, the most commonly used dosage forms, frequently exhibit delayed onset of action due to slow dissolution and variable gastrointestinal absorption. Swallowing difficulties, particularly in pediatric, geriatric, and critically ill patients, further compromise patient compliance. In addition, many antithrombotic drugs undergo extensive hepatic first-pass metabolism, leading to reduced bioavailability and inter-individual variability in therapeutic response?. Parenteral formulations such as injections provide rapid systemic drug levels but require trained healthcare professionals, sterile conditions, and are unsuitable for self-administration or early intervention outside hospital settings.These challenges have driven the search for alternative drug delivery platforms capable of providing rapid onset of action, ease of administration, and improved patient compliance. Among emerging drug delivery technologies, oral thin film (OTF) drug delivery systems have gained considerable attention in recent years. OTFs are ultra-thin, flexible polymeric films designed to disintegrate rapidly upon contact with saliva, releasing the drug for absorption through the buccal or sublingual mucosa?. This route of administration offers several advantages, including rapid drug release, partial avoidance of first-pass metabolism, water-free administration, and improved patient acceptability.Recent advances in pharmaceutical technology have further expanded the scope of OTFs by integrating nanotechnology, electrospinning, mucoadhesive systems, and three-dimensional (3D) printing. These innovations enable improved drug solubility, enhanced mucosal permeation, controlled drug release, and personalized dosing strategies. In the context of thrombosis therapy, where rapid and reliable drug action is critical, OTFs represent a promising and versatile delivery platform.This review aims to provide a comprehensive and up-to-date overview of oral thin film drug delivery systems for thrombosis therapy. The review systematically discusses thrombosis pathophysiology and drug targets, fundamentals of oral thin film technology, formulation components, manufacturing techniques, evaluation parameters, challenges in antithrombotic OTF development, recent research advances, and future prospects.

Table 1. Classification of Oral Thin Film Drug Delivery Systems

Table 2. Comparison of Oral Thin Films with Conventional Oral Dosage Forms

2. THROMBOSIS: PATHOPHYSIOLOGY AND THERAPEUTIC DRUG TARGETS

Thrombosis is a complex pathological process resulting from dysregulation of normal hemostasis. Under physiological conditions, hemostasis maintains blood fluidity while allowing rapid clot formation at sites of vascular injury. Pathological thrombosis occurs when this finely balanced system is disrupted, leading to inappropriate clot formation within intact blood vessels?. The process involves coordinated interactions between the vascular endothelium, circulating platelets, plasma coagulation factors, and the fibrinolytic system.

2.1 Hemostasis and Thrombus Formation

Hemostasis occurs in three overlapping phases: primary hemostasis, secondary hemostasis, and fibrinolysis.

• Primary hemostasis involves platelet adhesion, activation, and aggregation at the site of endothelial injury.
• Secondary hemostasis involves activation of the coagulation cascade, leading to thrombin generation and fibrin formation.
• Fibrinolysis ensures controlled clot dissolution after vascular repair.

Pathological thrombosis results when procoagulant forces outweigh natural anticoagulant and fibrinolytic mechanisms, leading to excessive thrombin generation and fibrin deposition?.

2.2 Virchow’s Triad

Virchow’s triad remains the cornerstone concept for understanding thrombogenesis and includes three major contributing factors?:

1. Endothelial injury or dysfunction:
   Damage to the endothelium due to atherosclerosis, inflammation, trauma, or oxidative stress exposes subendothelial collagen and tissue factor, triggering platelet adhesion and coagulation cascade activation.
2. Abnormal blood flow:
   Stasis or turbulent blood flow promotes accumulation of clotting factors and platelets, particularly in venous circulation and cardiac chambers.
3. Hypercoagulability:
   Inherited or acquired conditions such as cancer, pregnancy, antiphospholipid syndrome, and genetic mutations increase the tendency for clot formation.

2.3 Arterial vs Venous Thrombosis

Thrombi differ significantly based on their site of formation:

• Arterial thrombosis occurs under high shear conditions and is predominantly platelet-rich (“white thrombi”). It is commonly associated with atherosclerosis and is responsible for myocardial infarction and ischemic stroke?.
• Venous thrombosis forms under low-flow conditions and is fibrin-rich (“red thrombi”), often involving trapped red blood cells. It leads to deep vein thrombosis and pulmonary embolism¹?.

These fundamental differences dictate therapeutic strategies and drug selection.

3. ANTITHROMBOTIC DRUG CLASSES AND MECHANISMS

Pharmacological management of thrombosis primarily targets platelet function, coagulation pathways, or fibrin degradation. The therapeutic effectiveness of these drugs depends on rapid absorption, predictable pharmacokinetics, and consistent systemic exposure—factors that strongly support the need for advanced delivery systems such as oral thin films.

3.1 Anticoagulants

Anticoagulants inhibit various steps of the coagulation cascade and prevent fibrin clot formation. They are the mainstay therapy for venous thromboembolism and atrial fibrillation.

Vitamin K antagonists:
Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, and X). Although effective, it has a narrow therapeutic window, delayed onset of action, food and drug interactions, and requires frequent monitoring¹¹.

Heparins:
Unfractionated heparin and low-molecular-weight heparins enhance antithrombin III activity, leading to inhibition of thrombin and factor Xa. They provide rapid anticoagulation but require parenteral administration.

Direct oral anticoagulants (DOACs):
Drugs such as rivaroxaban and apixaban (factor Xa inhibitors) and dabigatran (direct thrombin inhibitor) offer predictable pharmacokinetics and fewer interactions. However, oral absorption variability and delayed onset remain concerns in emergency situations¹².

3.2 Antiplatelet Agents

Antiplatelet drugs play a central role in the prevention and treatment of arterial thrombosis.

Cyclooxygenase inhibitors:
Aspirin irreversibly inhibits cyclooxygenase-1 (COX-1), reducing thromboxane A? synthesis and platelet aggregation¹³.

P2Y12 receptor antagonists:
Clopidogrel, prasugrel, and ticagrelor inhibit ADP-mediated platelet activation. Rapid platelet inhibition is crucial in acute coronary syndromes and stent thrombosis prevention¹?.

The onset of action of oral antiplatelet tablets is often delayed due to gastrointestinal absorption variability, making them ideal candidates for fast-dissolving oral thin films.

3.3 Fibrinolytic Agents

Fibrinolytic or thrombolytic agents dissolve existing clots by converting plasminogen to plasmin.Common agents include alteplase, reteplase, and streptokinase. These drugs are primarily administered intravenously due to their large molecular size and instability. Although oral thin films are not currently used for fibrinolytics, emerging delivery technologies suggest potential future applicability for selected low-dose or adjunct therapies¹?.

Table 3. Antithrombotic Drug Classes, Targets, and Clinical Applications

Relevance to Oral Thin Film Drug Delivery

The therapeutic success of antithrombotic agents is strongly influenced by the speed and reliability of drug absorption. Delayed or inconsistent absorption can result in inadequate platelet inhibition or anticoagulation, increasing the risk of adverse cardiovascular events. Oral thin film drug delivery systems provide a promising alternative by enabling rapid drug release, potential transmucosal absorption, and improved patient compliance—particularly in emergency and high-risk populations¹?.

4. ORAL THIN FILM DRUG DELIVERY TECHNOLOGY

Oral thin film (OTF) drug delivery systems are ultra-thin, flexible polymeric dosage forms designed to deliver drugs through the oral mucosa. Typically, OTFs range from 20 to 200 μm in thickness and are formulated to rapidly hydrate, swell, and disintegrate upon contact with saliva, releasing the drug for local or systemic absorption¹?. Depending on formulation design, drugs may be absorbed through the buccal, sublingual, or oropharyngeal mucosa.

4.1 Mechanism of Drug Release and Absorption

Upon placement in the oral cavity, saliva penetrates the polymeric matrix, leading to hydration and polymer relaxation. This process allows rapid drug diffusion from the film surface. Drug absorption may occur via:

• Transcellular pathway (through epithelial cells)
• Paracellular pathway (between epithelial cells)

Highly vascularized oral mucosa enables rapid systemic uptake, bypassing or partially avoiding hepatic first-pass metabolism. This is particularly advantageous for antithrombotic drugs that require rapid onset and predictable plasma concentrations¹?.

4.2 Suitability of OTFs for Thrombosis Therapy

Thrombosis management often demands immediate pharmacological action, especially in acute coronary syndromes, stroke prevention, and venous thromboembolism. OTFs offer:

• Rapid drug release and onset
• Ease of administration without water
• Improved patient compliance
• Reduced inter-individual variability
• Potential pre-hospital or emergency use

These advantages make OTFs highly suitable for delivering antiplatelet and selected anticoagulant agents in time-critical scenarios¹?.

5. FORMULATION COMPONENTS OF ORAL THIN FILMS

The performance of oral thin films depends heavily on careful selection and optimization of formulation components. Each excipient plays a specific role in determining mechanical strength, disintegration behavior, drug release, stability, and patient acceptability.

5.1 Film-Forming Polymers

Film-forming polymers constitute the structural backbone of OTFs. Ideal polymers should be non-toxic, non-irritant, tasteless, flexible, and capable of forming uniform films.

Commonly used polymers include:

• Hydroxypropyl methylcellulose (HPMC)
• Polyvinyl alcohol (PVA)
• Pullulan
• Sodium alginate
• Chitosan

The type and concentration of polymer influence film thickness, tensile strength, disintegration time, and drug release kinetics²?.

5.2 Plasticizers

Plasticizers are incorporated to improve flexibility and prevent brittleness. They reduce intermolecular forces between polymer chains, enhancing film elasticity.Common plasticizers include glycerol, polyethylene glycol (PEG 400), propylene glycol, and triacetin. Excessive plasticizer content may compromise mechanical strength and increase tackiness²¹.

5.3 Surfactants and Permeation Enhancers

Surfactants such as Tween 80 and sodium lauryl sulfate improve wetting and solubilization of poorly water-soluble drugs. Permeation enhancers (e.g., cyclodextrins, fatty acids, bile salts) transiently increase mucosal permeability, facilitating drug transport across the oral epithelium²².

5.4 Saliva Stimulants, Sweeteners, and Flavoring Agents

Saliva stimulants (citric acid, malic acid) promote rapid film hydration and disintegration. Sweeteners and flavoring agents such as sucralose, mannitol, and peppermint oil improve palatability, which is essential for patient compliance during chronic antithrombotic therapy.

Table 4. Formulation Components Used in Oral Thin Films and Their Functional Roles²³

6. MANUFACTURING TECHNIQUES FOR ORAL THIN FILMS

Several manufacturing techniques are employed for producing oral thin films. The selection of an appropriate method depends on drug properties, desired release characteristics, scalability, and cost considerations²⁴.

6.1 Solvent Casting Method

Solvent casting is the most widely used technique for laboratory-scale and commercial production of OTFs. It involves dissolving polymers and excipients in a suitable solvent, followed by incorporation of the drug, casting, drying, and cutting into uniform films²⁵.

Advantages:

• Simple and reproducible
• Suitable for thermolabile drugs
• Produces smooth and uniform films

Limitations:

• Long drying time
• Risk of residual solvents

6.2 Hot-Melt Extrusion

Hot-melt extrusion involves melting and mixing polymers and drugs at elevated temperatures, followed by extrusion into thin films. This solvent-free technique is suitable for continuous manufacturing and industrial scale-up²⁶.

Limitations: Not suitable for heat-sensitive drugs.

6.3 Electrospinning

Electrospinning is an advanced technique used to produce nanofiber-based oral thin films with extremely high surface area. Electrospun films exhibit ultrafast dissolution and enhanced drug bioavailability, making them ideal for emergency antithrombotic therapy²⁷.

6.4 Three-Dimensional (3D) Printing

3D printing allows precise control over film thickness, drug dose, geometry, and release behavior. This technique enables personalized medicine approaches, particularly useful for antithrombotic drugs with narrow therapeutic windows²⁸.

Table 5. Manufacturing Techniques for Oral Thin Films: Advantages and Limitations²⁹

7. EVALUATION AND QUALITY CONTROL OF ORAL THIN FILMS

Comprehensive evaluation of oral thin films (OTFs) is essential to ensure quality, safety, efficacy, and patient acceptability. Evaluation parameters include physicochemical, mechanical, in vitro, ex vivo, and stability studies³⁰.

7.1 Physical Evaluation

Appearance and Organoleptic Properties:
Films should be smooth, uniform, transparent or translucent, and free from air bubbles, cracks, or particulate matter. Taste and mouthfeel are evaluated subjectively to ensure patient acceptability³¹.

Thickness Uniformity:
Measured using a micrometer screw gauge or digital caliper at multiple points. Uniform thickness ensures dose accuracy and consistent drug release.

Weight Variation:
Individual film units are weighed to assess uniformity of drug distribution across the film matrix³².

7.2 Mechanical Properties

Mechanical strength determines film integrity during handling, packaging, and administration.

• Tensile strength: Resistance to breaking under tension
• Percentage elongation: Measure of film flexibility
• Young’s modulus: Indicator of film stiffness
• Folding endurance: Number of times a film can be folded without breaking (ideally >300 folds)

7.3 Surface pH

Surface pH is measured by placing the film in contact with distilled water. The pH should be within the physiological range (6.0-7.4) to avoid mucosal irritation³³.

7.4 Disintegration Time

Fast-dissolving OTFs should disintegrate within 10-30 seconds. Disintegration is assessed using a petri dish method or modified USP disintegration apparatus³⁴.

7.5 In Vitro Dissolution Studies

Drug release is evaluated using:

• USP type II (paddle apparatus)
• Simulated saliva fluid (pH 6.8)
• Temperature: 37 ± 0.5°C

Rapid and complete drug release within a few minutes is desirable for antithrombotic therapy.

7.6 Content Uniformity

Ensures that each film contains the intended drug dose. Drug content is analyzed using UV-visible spectroscopy or HPLC.

7.7 Ex Vivo Permeation Studies

Ex vivo permeation studies are conducted using Franz diffusion cells with porcine or bovine buccal mucosa. These studies assess the rate and extent of transmucosal drug absorption.

7.8 Stability Studies

Stability studies are performed according to ICH Q1A(R2) guidelines:

• 40°C ± 2°C / 75% RH ± 5% for 6 months
  Films are evaluated for changes in appearance, drug content, mechanical properties, and dissolution behavior.

Table 6. Evaluation Parameters and Acceptance Criteria for Oral Thin Films³⁵

8. CHALLENGES AND LIMITATIONS IN ANTITHROMBOTIC OTF DEVELOPMENT³⁶

Despite significant advantages, several challenges limit the widespread clinical application of OTFs in thrombosis therapy.

8.1 Dose Limitation

OTFs typically accommodate ≤30-40 mg of drug. Many anticoagulants require higher doses, necessitating dose-reduction strategies such as nanotechnology-based delivery or use of highly potent drugs.

8.2 Drug Stability

Antithrombotic agents like aspirin are moisture-sensitive and prone to degradation. Incorporation of stabilizers and moisture-resistant packaging is essential.

8.3 Taste Masking

Most antithrombotic drugs possess a bitter taste. Effective taste-masking strategies are critical to ensure patient compliance, especially for chronic therapy.

8.4 Controlled Drug Release

While immediate-release OTFs are easily formulated, achieving sustained or controlled release through oral films requires complex polymer combinations and remains a formulation challenge.

8.5 Regulatory and Manufacturing Challenges

Lack of standardized regulatory guidelines for OTFs and challenges in large-scale manufacturing and uniformity remain barriers to commercialization.

              Table 7. Challenges in Antithrombotic Oral Thin Film Development and Possible Solutions³⁷